Abstract
Introduction
Adult T-cell leukaemia/lymphoma (ATLL) is an aggressive T-cell non-Hodgkin's lymphoma (NHL) initially described in 1977 (1) and soon after demonstrated to be associated with the retrovirus human T-cell lymphotropic virus type 1 (HTLV-1) (2).
HTLV-1 is endemic in the Caribbean basin, parts of Central and South America, Central Africa, regions of Japan and Iran. In the United Kingdom it is estimated that 22,500 people are infected with HTLV-1 and infection is most frequent in individuals of Afro-Caribbean or African origin (3) . HTLV-1 is frequently transmitted from mother to child via breast feeding and several strands of evidence point to the importance of early childhood infection in the development of ATLL: the prolonged period between infection and presentation with disease and the high prevalence of HTLV-1 infection in mothers of patients with ATLL compared with other HTLV-1-associated diseases (4) . Between 3-5% of individuals who become infected with HTLV-1 before the age of 20 will develop ATLL and risk of leukaemia has been associated with acquisition of infection in early life (5, 6) and with high HTLV-1 proviral load in adults (7) .
ATLL is classified according to the criteria of Shimoyama (8) . Sub-classification into acute, lymphoma, chronic or smouldering ATLL is based on lymphocyte count, abnormal lymphocyte percentage, lactate dehydrogenase (LDH), corrected calcium and pattern of tissue involvement. Median survival of patients with acute and lymphoma ATLL was 6 and 10 months, and projected four-year survival rates 5 and 6%, respectively. These two subtypes represent 'aggressive' ATLL, the median survival in patients with chronic ATLL being 24 months (7).
The reported incidence of ATLL in the United Kingdom is 14-16 cases per annum (9) . Between 1996-9 all 37 cases in the UK were in England and diagnosed in patients of Afro-Caribbean origin (3). The mean age at presentation was 40 years, similar to other series of Afro-Caribbean patients (10, 11) and a decade younger than in Japanese patients (12, 13) .
ATLL was first reported in the UK in 1982 in six Afro-Caribbean patients aged who underwent brief remissions to combination chemotherapy (14) . Further UK experience is limited to two case series and two prospective studies. In both case series, including 52 and 21 patients respectively, median overall survival (OS) was only 6 months (15, 16) . In 2001 a prospective study assessed the tolerability and efficacy of zidovudine (ZDV) and interferon-α (IFN-α) in 15 subjects and compared to historical controls. Most patients had acute ATLL. Twelve had received prior chemotherapy, including one of two with smouldering ATLL. The response rate was 67% and the difference in survival between responders and non-responders was significant (p=0.002) suggesting a benefit with use of ZDV and IFN-α. The median OS from first presentation was 18 months (17) . Most recently a phase 2 study assessed the addition of an anti-CD25 monoclonal antibody (Daclizumab) to first line therapy with cyclophosphamide, Adriamycin (doxorubicin), Oncovin (vincristine), prednisolone (CHOP), in 10 subjects with aggressive ATLL (18) . The overall response rate was 70% with five patients entering CR, which was maintained for 24 months in two cases. However disease progression and early relapse was typical and seven patients died 4-19 months from diagnosis.
The aim of this study was to describe aggressive ATLL treatment patterns in England and compare outcomes to published data. In particular the impact of therapy with zidovudine and interferon-alpha (ZDV/IFN-α) was assessed in view of the reported efficacy in ATLL (17, 19, 20) .
Methods

Subjects
We conducted a retrospective analysis of data from patients diagnosed with aggressive ATLL in England between January 1999 and December 2009.
Participating centres specialized in the treatment of aggressive lymphomas or had a relatively high incidence of ATLL. Patient data were obtained from medical records according to the study proforma and included demographic data, disease subtype, treatment, response and survival and were anonymised for analysis. Patient characteristics are summarised in Table 1 .
Six patients treated palliatively due to poor performance status and co-morbidities, including two given low dose AVT alone for up to 14 days, died soon after diagnosis and were not included in the treatment analyses.
Results
Treatment
Of the 67 patients who received chemotherapy as first line treatment 27 had acute ATLL and 40 lymphoma ATLL. In 54 patients without CNS involvement the chemotherapy regimen was CHOP alone (n=45), CHOP with the anti-CD25 monoclonal antibody Daclizumab (CHOP-Z; n=7) or Gemcitabine/Carboplatin (n=2).
Thirty-four (63%) received prophylactic intra-thecal chemotherapy (ITC). Of the 13 with CNS involvement six received CHOP (with Daclizumab in three patients) and additional ITC while the other seven were treated with high dose IV methotrexate (n=5) or cytarabine (n=2) containing regimens. The use of prophylaxis against opportunistic infection (OI) was documented in 62% of cases, and included co-trimoxazole or dapsone, aciclovir and fluconazole or itraconazole.
Response to first line treatment
Treatment response data were available for 65/67 patients receiving first line chemotherapy. The response rate in patients receiving 'combined first line therapy' was 81% and in those receiving chemotherapy alone, 49% (p<0.01, Odds ratio 4.42) ( Table 2) . Median OS for all with CNS disease at presentation (n=13) was 10.5 months. Seven (54%) were given AVT, as 'combined first line therapy' in three and 'deferred' in four.
In this subset the median OS with AVT at anytime was 21.5 months compared with 2.3 months for CNS disease treated without AVT.
Multivariate analysis identified 'use of AVT at any time' as the only factor to reduce risk of death (p=0.002; hazard ratio 0.23, 95% CI 0.091-0.60). Other factors included in the analysis were sex, age, disease subtype, LDH, Calcium, lymphocyte count at presentation, bone marrow (BM), liver or spleen involvement.
Timing of AVT was then assessed. While 'combined first line therapy', when compared to chemotherapy alone, was associated with prolonged cumulative OS in both acute (p=0.0081) ( Figure 3A) and lymphoma (p=0.001) (Figure 3B ) ATLL, AVT was also effective when used after relapse ('deferred therapy'). Of those patients 
Discussion
Although retrospective, this analysis provides a timely assessment of the diagnosis and treatment of 'aggressive' ATLL in England. A median age at diagnosis of 58 years, while higher than initial reports of ATLL in England and the Caribbean (11, 15) is comparable both to more recent UK reports (16, 17) and to Japanese data (12) .
Disease is more common in females in common with all previous reports of ATLL in the UK and the Caribbean and in contrast with Japan where ATLL is more frequent in males (12) . Almost twice as many cases of aggressive ATLL were lymphoma, in contrast to the original Shimoyama cohort (8) and previous British studies where acute ATLL was more frequent (15) (16) (17) and to a 2010 meta-analysis in which the ratio was approximately 1:1 (22) .
We have demonstrated that inclusion of ZDV/IFN-α, both in 'combined first-line therapy' and in 'deferred therapy' in aggressive ATLL is associated with improved survival compared to chemotherapy alone. These data support the recent retrospective meta-analysis, where the use of ZDV/IFN-α was shown to be beneficial in acute ATLL, whilst adding evidence of benefit in lymphoma ATLL.
In acute ATLL our response rate for chemotherapy with AVT is 58% with a CR rate of 42%. Chemotherapy alone was inferior with a CR rate of 31% comparable to the 30% CR rate with AVT alone in the recent meta-analysis (22) . With the exception of the LSG-15 regimen (23), increased response rates following chemotherapy intensification have not been accompanied by significantly improved survival (24) . In our study three out of 12 patients treated with combined first line therapy remained alive after median 22 months follow up while no patient treated with chemotherapy alone survived more than 12 months. However two of these three received alloSCT in first remission. Thus, although we demonstrate superiority of combined first line therapy over chemotherapy alone, the impact on survival remains disappointing, and alloSCT should be considered in all cases where satisfactory overall response has been attained, ideally in the context of a clinical trial. We do not attempt to compare with the 'AVT alone' approach as discussed in the meta-analysis where achievement of CR was associated with a significant benefit in survival. It should be noted that the typical doses of ZDV (1000mg per day) and IFN-α (10 MU daily) are higher when AVT used alone (19) .
In ATLL lymphoma we observed an ORR of 100% with 'combined first-line therapy' of which 36% were CR compared with 54% ORR with chemotherapy alone although the CR rate was similar (39%). In the meta-analysis, while AVT alone was associated with a survival disadvantage compared with chemotherapy with or without maintenance AVT (median OS 7 months, no patient surviving beyond 18 months), an analysis of the impact of AVT combined with chemotherapy in first line therapy was not made. In our study 6% of patients treated with chemotherapy alone remained alive at 3 years whilst with 'combined first-line therapy' 27% survived 3 years with no additional mortality predicted at 6 years. These data would suggest that a combined therapy approach is superior to chemotherapy alone in ATLL lymphoma. In efforts to optimize the chemotherapy alone approach the LSG 15 study group in Japan demonstrated improved CR rates with intensification of chemotherapy compared with biweekly CHOP (40% v 25%) although ORR remained around the 70% mark. This approach resulted in a median OS of 13 months with a 3-year OS of 24% which is comparable to results observed in our study without recourse to chemotherapy intensification. No studies have been performed to test the combination of higher intensity schedules with AVT and this may not be feasible due to toxicity concerns.
The optimal timing for administration of AVT in aggressive ATLL remains to be determined. The observation that survival curves for patients treated with 'combined first-line therapy' or 'deferred therapy' are almost identical suggests that there is no difference and AVT could be deferred to relapse. Two factors argue against such an approach. Firstly response rates are improved by 'combined first-line therapy' over 'chemotherapy alone' and therefore more patients treated with such an approach could be considered for potentially curative alloSCT if eligible. Secondly patients receiving 'deferred AVT' in our study may be biased towards better outcome as they have already survived to the point where second line therapy is considered. Finally, in a recent phase two study evaluating use of AVT after response to first line chemotherapy, only eight out of 19 patients were eligible for AVT, the others having progressed or being withdrawn through toxicity (25) .
Although not the subject of this analysis the low rates of OI support the widespread use of antimicrobial prophylaxis. In addition, since CNS disease was frequent (18%) early CSF analysis and administration of prophylactic chemotherapy is also recommended. The use of AVT, which penetrates CSF, seems to provide additional benefit.
Despite these results the survival of patients with aggressive ATLL remains poor.
Whilst chemotherapy resistance is frequent and well documented it is clear from our results and those from the recent meta-analysis, which together provide survival data on 145 patients with aggressive ATLL treated with AVT, that prognostic indicators to guide therapy would inform therapeutic decision-making. The presence of wild type p53 is reported to influence the response to ZDV (26) whilst expression of IRF4 modifies response to . Further analysis of the predictive value of these and other markers should be a priority in future studies.
The heterogeneity of the patients in this study in terms of prior treatment and time to initiating AVT is recognized. Being a retrospective analysis there is always concern that channelling bias of patients with milder or more responsive disease towards AVT may occur. We have attempted to address this by the multivariate analysis and by exploring differences in the timing of ZDV/IFN. We have no evidence that this was driven by patient characteristics but was influenced by local practice. Thus some centres did not start ZDV/IFN at all, some as combined first line therapy and others at relapse.
On the basis of these data we recommend that low dose AVT should be added when Tables and Figures   Table 1 -Patient characteristics   Table 2 -Response to first line therapy 
